Challenges in the management of severe asthma: Role of current and future therapies

Current Pharmaceutical Design

Volumn 17, Issue 7, 2011, Pages 703-711

  Oliveinstein, Ron ^a   Jahdali, Hamdan Al ^b   Alkhamis, Nouf ^b,c   Halwani, Rabih ^b   Al Muhsen, Saleh ^b,c   Hamid, Qutayba ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Biologic agents; Corticosteriods; Macrolides; New asthma therapy; Severe asthma

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALTRAKINCEPT; AURANOFIN; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; FLUTICASONE; GOLD SALT; GOLIMUMAB; INFLIXIMAB; KELIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHOTREXATE; MOMETASONE FUROATE; OMALIZUMAB; PASCOLIZUMAB; PLACEBO; PREDNISONE; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; ANTIASTHMATIC AGENT; MACROLIDE;

ASTHMA; CATARACT; CHLAMYDIAL PNEUMONIA; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; GLAUCOMA; HERPES ZOSTER; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG FUNCTION TEST; MYCOPLASMA PNEUMONIA; MYOPATHY; OBESITY; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROLOGY; SIGNAL TRANSDUCTION; STOMATITIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; URTICARIA; ANIMAL; DISEASE MANAGEMENT; DRUG COMBINATION; FORECASTING; HOSPITALIZATION; IMMUNOLOGY; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; MACROLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 79954562341     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795428993     Document Type: Review

References (154)

1. Robinson DS et al. Predominant TH2-like bronchoalveolar Tlymphocyte population in atopic asthma. New Engl J Med 1992; 326 (5): 298-304.
2. Bradley BL et al. Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88(4): 661-74
3. Ying S et al. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and Th1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12(5): 477-87.
4. Bergeron C et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkaneflunisolide. J Allergy Clin Immunol 2005; 116: 983-9.
5. Procceedings of the ATS Workshop on Refractory Asthma. Current Understanding, Recommendations and Unanswered Questions. Am J Respir Crit Care Med 2000; 162: 2341-51.
6. Antonicelli L et al. Asthma severity and medical resource utilization. Eur Respir J 2004; 23: 723-9.
7. The ENFUMOSA STUDY GROUP. The ENFUMOSA crosssectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-7.
8. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline defined asthma control be achieved? Thr Gaining Optimal Asthma ControL study. Am J Respir crit Care Med 2004; 170: 836-44.
9. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years and over. J Asthma 2006: 43: 75-80.
10. Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008; 179: 1121-31.
11. Hermosa JL, Sanchez CB, Rubio MC, Minguez MM, Walther JL. Factors associated with the control of severe asthma. J. Asthma 2010; 47: 124-30.
12. Weinstein AG. Should patients with persistent severe asthma be monitored for medication adherence. Ann Allergy Asthma Immun 2005; 94(2): 251-7.
13. Gamble J, Stevenson M, McLean E, Heany LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-22.
14. Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133: 420-6.
15. D'Sousa WJ, Te Karu H, Fox C, et al. Longterm reduction in asthma morbidity following an asthma self-management programme. Eur Respir J 1998; 11(3): 611-6.
16. Heany LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003; 58: 561-6.
17. Le Moual N, Siroux V, Pin I, Kauffman F, Kennedy SM. Asthma severity and exposure to occupational asthmogens. Am JResp[ir Crit Care Med 2005; 172: 440-5.
18. Bachert C, Paton J, Van Cauwenberg P. The role of sinus disease in asthma. Curr Opinion Allergy Clin Immunol 2006; 6: 29-36.
19. Koga T, Oshita Y, Kamimura T, Koga H, Aizawa H. Characterisation of patients with frequent exacerbation of asthma. Respir Med 2006; 100: 273-8.
20. Littner MR, Leung FW, Ballard ED, Huang B, Samra NK. Lansoprazole Asthma Study Group. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005; 128: 1128-35.
21. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173(10): 1091-7.
22. Lafond C, Series F, Lemiere C. Impact of CPAP on asthmatic patients with obstructive sleep apnea. Eur Respir J 2007; 29: 307-11.
23. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-33.
24. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma 2007.
25. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma summary report 2007. J Allergy Clin Immunol 2007; 120: S94-S138.
26. Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol 2010; 125: 285-92.
27. Sobande PO, Kercsmar CM. Inhaled steroids in asthma management. Respir Care 2008; 53: 625-33.
28. Usmani OS, Ito K, Maneechotessawan K, et al. Glucocorticoreceptor receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704-12.
29. Nino G, Hu A, Grunstein JS, Grunstein MM. Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of longacting beta2-adrenoceptor agonist exposure. J Allergy Clin Immunol 2010; 125: 1020-7.
30. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997; 337: 1405-11.
31. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
32. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65: 39-43.
33. Brightling CE. Clinical applications of induced sputum. Chest 2006; 29: 1344-8.
34. Dente FL, Bacci E, Bartoli ML, et al. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2010; 104: 464-70.
35. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma therapy by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-94.
36. Nelson HS, Gallegos CM, Silveira LJ, Newell JD, Gelfand EW. Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. Allergy Asthma Proc. 2009; 30: 284-92.
37. Cohen J, Douma WR, ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008; 31: 1213-20
38. Berger WE. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 2006; 1: 265-70.
39. Faul JL, Torrney VJ, Leonard C, Burke CM, et al. Lung immunopathology in cases of sudden asthma death. Eur Respir J 1997; 10: 301-7.
40. Christodoulopoulos P, Leung DY, Elliott MW, et al Increased numbers of glucocorticoid receptor-beta-expressing cells in airways in fatal asthma. J Allergy Clin Immunol 2000; 106: 479-84.
41. Wenzel SE, Szefler SJ, Leund DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-43.
42. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122: 510-516.
43. Ohbayashi H. One-year evaluation of the preventative effect of hydrofluoroalkane-beclomethasonedipropionate on eosinophilic inflammation of asthmatic peripheral airways. Respiration 2007; 74: 146-153.
44. Ohbayashi H, Adachi M. Hydrofluoroalkane-Beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double-cross study. Allergology International 2008; 57: 1-9
45. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-1222
46. Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Int J Clin Pract 2004; 58: 678-688
47. Gibson PG. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J 2005; 25: 397-9.
48. Lundborg M, Wille S, Bjermer et al. Maintenance plus budesonideformoterol compared with a high maintenance dose of budesonideformoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2005; 22: 809-21.
49. Fitzgerald JM, Boulet L-P, Follows RMA. The CONCEPT trial: a1-year,multicenter, randomized double-blind, double-dummy comparison of a stable dosing regimen of salmeterol-fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/ budesonide in adults with persistent asthma. Clin Ther 2005; 27: 393-406.
50. Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide-formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Resp Opin 2004; 20: 1403-18.
51. Rabe KF, Pizzichini E, Stillberg B et al. Budesonide-formoterol in a single inhaler for maintenance and relief in mild to moderate asthma. A randomized double-blind trial. Chest 2006; 129: 246-56.
52. O'Byrne PM, Bisgaard H, Godard PP et al Budesonide-formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 172: 410-12.
53. Bisgaard H, LeRoux P, Bjamer D et al.Budesonide-formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130: 1733-43.
54. Vogelmaier C, D'Urzo A, Pauwels R et al.Budesonide-formoterol maintenance and reliever therapy: an effedctive asthma treatment option? Eur Respir J 2005; 26: 819-26.
55. Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized, controlled double-blind study Lancet 2006; 368: 744-53.
56. Kuna P, Peters J, Buhl R. Budesonide-formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide-formoterol or salmeterolfluticasone. Eur Respir J 2006; 28(suppl 50): 205s.
57. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165(1): 9-14.
58. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma. Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170: 601-5.
59. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27(3): 483-94.
60. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized, controlled trial 2007; Am J Respir Crit Care Med 176(3): 231-7.
61. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992; 16: 411-23.
62. Snier RJ, Nunn AJ, Chung KF et al. Randomized double-blind placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.
63. Aaron S and Dales R. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med 1998; 92: 1059-65.
64. Kuitert LM and Harrison AC. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.Thorax 1991: 46: 936-7.
65. Morice AH, and Lai WK. Fatal varicella zoster infection in a severe steroid-dependent asthmatic patient receiving methotrexate. Thorax 1995; 50: 1221-2.
66. Fukuda T, Asakowa J, Motojima S, et al. Cyclosporin A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Annals Allergy Asthma Immunol 1995; 75: 65-72.
67. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporine in corticosteroid-dependent chronic cevere asthma. Lancet 1992; 339: 324-8.
68. Lock S, Kay A, Barnes N et al. Double-blind placebo-controlled study of cyclosporine A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-14.
69. Szczeklik A, Nizankowska B, Dworski R et al. Cyclosporin for steroid-dependent asthma. Allergy 1991; 46: 312-5.
70. Bernstein IL, Bernstein DI, Dubb JW et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with cortcosteroid-dependent asthma: Auranofin Multicenter Drug trial. J Allergy and Clin Immunol 1996; 98: 317-24.
71. Martin RJ, Kraft M, Chu HW et al. A link between chronic asthma and chronic infection. J Allergy and Clin Immunol 2001; 107: 595-601.
72. Allegra L, Blasi F, Centanni S et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J 1994; 7: 2165-8.
73. Biscardi S, Lorrot M, Marc E et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004; 38: 1341-6.
74. Garey KW, Alwani A, Danziger LH, Rubinstein IR. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary disease. Chest 2003; 123: 261-5.
75. Terao H, Asano K, Kanai K, et al. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm 2003; 12: 195-202.
76. Black PN. Anti-inflammatory effects of macrolide antibiotics.
77. r Respir J 1997; 10: 971-2.
78. Simpson JL, Powell H, Boyle MJ, Scott RJ, and Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177: 148-155.
79. Garey KW, Rubinstein I, Gotfried MH, Khan J, Varma S, and Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone dependent asthma. Chest 2000; 118: 1826-7.
80. Ekichi A, Ekichi M, Erdemoglu AK. Effect of azithromycin on the severity of bronchial hypperesponsiveness in patients with mild asthma. J Asthma 2002; 39(2): 181-5.
81. Kraft M, Casell G, Pak J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest 2002; 21: 1782-88.
82. Tarantini F, Balardini I, Passalaqua G, Brado F, Canonica GW. Asthma treatment: 'magic bullets which seek their own targets'. Allergy 2007; 62: 605-10.
83. Presta LG, Lahr SI, Shields RI, et al. Humanization of an antibody directed against IgE. J Immunol 1993: 151: 2623-32.
84. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 2006; %33: 302-7.
85. Hendeles I, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother 2007; 41: 1397-1410.
86. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin2003; 19: 491-8.
87. Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006; 117: 1230-2.
88. Poole JA, Matangkasombul P, Rosewasser LJ. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol 2005; 115: S376-S385.
89. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. Yhe anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65.
90. Brownell I, Casale TB. Anti-IgE therapy.Immunol Allergy Clin North Am 2004; 24: 551-68.
91. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100: 1907-17.
92. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody, rhu-MAb-E25 study group. New Engl J Med 1999; 341: 1966-73.
93. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16.
94. Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr med res Opin 2001; 17: 233-240.
95. Babu KS, Arshad SH, Holgate ST. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin Biol Ther 2001; 1: 1049-58.
96. Berger P, Scotto-Gomez E, Molimard M, et al. Omalizumab decreases non-specific airway hypperresponsiveness in vitro. Allergy 2001; 62: 154-161.
97. Boushey HA jr. Experiences with monoclonal antibody therapy for allergic asthma. J Aleergy Clin Immunol 2001; 108: S77-S83.
98. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007: 99: 190-3.
99. Leynadier F, Doudou O, Gaouar H et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113: 360-1.
100. Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Succesful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy and Clin Immunol 2007; 120: 213-15.
101. Glavina-Biancha P, Glavina-Bianca M, Agondi R, Kalai J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119: 1279-80.
102. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007; 120: 979-81.
103. Leung DV, Bock SA. Progress in peanut allergy research: are we close to a cure? J Allergy Clin Immunol 2003; 112: 12-14.
104. Randhawa I, Chin T, Nussbaum E. Resolution of corticosteroidinduced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009; 46: 445-7.
105. Van der ENT CK, Hoekstra H, Rijkers GT. Successfuk treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62(3): 276-7.
106. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).
107. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007.
108. Marcus P. incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 2006, 129: 466-74.
109. Nopp A, Johansson SG, Adedoyin J, Palmqvist M, Oman H. After 6 years with Xolair; a 3 year withdrawal follow-up Allergy 2010; 65(1): 56-60.
110. Busse WW, Israel E, Nelson HS, Baker JW et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma. Am J Respir Crit Care Med 2008; 178: 1002-8.
111. Kon OM, Sihra BS, Compron CH, Leonard TB, Kay AC, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody in CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352; 1109-13.
112. Kon OM, Sihra BS, Loh LC, Barkans J et al. The effects of an anti- CD4 monoclonal antibody, keliximab, on peripheral CD4+T-cells in asthma. Eur Respir J 2001; 18: 45-52.
113. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-9.
114. Makino S, Fukuda T. Eosinophils and allergy in asthma. Allergy Proc 1995; 16: 13-21
115. Kotsimbos AT, Hamid Q. IL-5 and IL-5 receptor in asthma. Mem Inst Oswaldo Cruz 1997; 92: 75-91.
116. Gleich GJ, Kita H. Bronchial asthma: lessons from murine models. Proc Natl Acad Sci USA 1997; 94: 2101-2.
117. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112: 1029-36.
118. Flood-Page P., Swenson C, Faiferman I, Matthews J, Williams M et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit care Med 2007; 176: 1062-71.
119. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, et al. Asthma exacerbation and sputum eosinophils counts: a randomized controlled trial. Lancet 2002 360: 1715-21.
120. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimidiatis A, Pizzichini E, et al. Mepolizumab for prednisone dependent asthma with sputum eosinophilia. New Engl J Med 2009; 360: 985-93.
121. Haldar P, Brightling CE, Hargadon B, Gupta S, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New Engl J Med 2009; 360: 973-84.
122. Nakajima H, Tokatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007; 142: 265-73.
123. Borish LC, Nelson HS, Corrren J, Bensch G et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963-70.
124. Borish LC, Nelson HS, Lanz MJ, Claussen L et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816-23.
125. Adcock IM. Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372: 1073-87.
126. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N et al. Preclinical efficacy and safety of pascolizumab (SB 240683) a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130: 93-100.
127. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007; 19: 676-80.
128. O'Byrne P, Boulet L-P, Gauvreau G, Leon F, Sari S, White B. A single dose of MEDI-528, a monoclonal antibody against interleukin- 9, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. Chest 2007; 132: 478.
129. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202: 175-90.
130. Yang G, Volk A, Petley T, Emmell E. et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004; 28: 224-32.
131. Bhowmick B, Singh D, Molfino N et al. A double-blind, plcebo controlled,study to assess the pharmokinetics, safety, and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma. ERS Conference 2008: 515S (abstract).
132. Wenzel S, Wilbrahim D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-31.
133. Getz EB, Wilbraham D, Lalor C, Longphre M, Fuller R. Pharmacokinetics and local tolerance of an IL-4/IL-13 antagonist inhalation powder in humans. ERS Conference 2008: 545S (abstract).
134. Howarth PH, Babu KS, Arshad AS, Lau I et al. Tumour necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-18.
135. Berry MA, Hargadon B, Shelley M, Parker D, Shaw SE, Green RH et al. Evidence for a role for tumour necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
136. Morjaria JB, Chaulan AJ, Bobu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomized, placebo controlled trial. Thorax 2008: 63: 584-91.
137. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, etal. The effects of a monoclonal antibody directed against tumour necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-62.
138. Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, doubleblind, placebo-controlled study of tumour necrosis factor alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-58.
139. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
140. Barnes P. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006: 109: 238-245.
141. The American Lung Association Asthma Clinic Research Centers. Clinical trial of low dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175: 235-42.
142. Bateman E, Izquerdo JL, Harnest U, et al. Efficacy and safety of Roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2008; 96: 649-57.
143. Duan W, Wong WS. Targeting mitogen-activated protein kinases for asthma. Curr Dug targets 2006; 7: 691-8.
144. Pelaia G, Cuda G, Vatrella A, Gallelli L, Cardoglin M, Marra M et al. Mitogen-activated protein kinases and asthma. J Cell Physiol 2005; 202: 642-653.
145. Munoz L, Ramsay EE, Manetsch M, Qi G, Peifer C, Laufer S, Ammit AS. Novel p38 MAPK inhibitor ML3403 has potent antiinflammatory activity in airway smooth muscle. Eur J Pharmacol 2010; 635: 212-18.
146. Norman P. A novel Syk kinase inhibitor suitable for inhalation: R- 343(?) - - WO-2009031011. Expert Opin Ther Pat 2009; 19: 1469-72.
147. Castro M, Musani AI, Mayse ML and Shargill NS. Bronchial thermoplasty: a novel technique in the treatment of severe asthma. Ther Adv Respir Dis 2010; 4: 101-116.
148. Cox G, Miller J, Mitzner W, and Leff A. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24: 659-63.
149. Cox G, Thomson N, Rubin N, Niven R et al. Asthma control during the first year of after bronchial thermoplasty. N Engl J Med 2007; 356: 1327-37.
150. Pavord I, Cox G, Thomson N, Rubin A et al. Safety and efficacy of bronchial thermoplasty in symptomatic severe asthma. Am J Respir Crit Care Med 2007; 176: 1185-91.
151. Castro M, Rubin A, Laviolette M, Fiterman J et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-124.
152. Cox G, Laviolette M, Rubin A and Thomson N. Longterm safety of bronchial thermoplasty (BT): 3 year studies from multiple studies. Am J Respir Crit Care Med 2009; 179: A2780.
153. Hassan M, Jo T, Risse PA, Tolloczko B, Lemiere C, Olivenstein R, Hamid Q, Martin JG. Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma. J Allergy Clin Immunol 2010; 125: 1037-45.
154. Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, Lemiere C, Olivenstein R, Ernst P, Hamid Q, Martin J. J Allergy Clin Immunol 2009; 124: 45-51.